1-6 The uniform application of heat to a localized tumour is difficult to achieve due to the inhomogeneous anatomy with large dielectric contrasts, intra-tumoural tissue heterogeneity and physiologic counter-regulation, making the prediction or measurement of the temperature distribution demanding. 7-9 The application of HT places high demands on both the applicator hardware and treatment planning to guarantee accurate steering and an effective, safe therapy. Similar to RT systems, HT applicator systems should not only include the hardware component but also integrate a software component, that is, suitable planning and control tools which allow predictive planning and steering of thermal dose administration.
| INTRODUCTION
Hyperthermia (HT) in conjunction with radiation therapy (RT) has long been employed as a method to increase therapeutic efficacy in certain tumours. [1] [2] [3] [4] [5] [6] The uniform application of heat to a localized tumour is difficult to achieve due to the inhomogeneous anatomy with large dielectric contrasts, intra-tumoural tissue heterogeneity and physiologic counter-regulation, making the prediction or measurement of the temperature distribution demanding. [7] [8] [9] The application of HT places high demands on both the applicator hardware and treatment planning to guarantee accurate steering and an effective, safe therapy. Similar to RT systems, HT applicator systems should not only include the hardware component but also integrate a software component, that is, suitable planning and control tools which allow predictive planning and steering of thermal dose administration.
Accurate exposure control to prevent under-exposed target regions and unwanted hotspots in healthy tissue require a precisely controlled applicator system (amplitude and phase), precise spatial positioning of the applicators with respect to the patient body, highresolution electromagnetic (EM) and thermal simulations considering at least the local anatomy and adequate tissue models (dielectric, thermal and perfusion). [10] [11] [12] Either a reliable prediction or a closedloop system with thermometry-based feedback is needed to ensure a good correlation between planned (applied) dose and the effectively deposited heat in specific tissues over the time of treatment.
Over the last decade, progress has been made in terms of improved treatment accuracy and treatment planning guidance. Paulides et al [13] [14] [15] showed that pre-treatment planning simulations and improvements in hardware elements (water bolus shape stability) as well as accurate patient positioning optimize the treatment quality in
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human head and neck cancer patients. Their approach involved 3-dimensional (3-D) patient-specific EM and thermal simulations, which improve focused deposition of energy and enable conformal, reproducible and adaptive HT applications.
Thermal dose quantities are intended to enable a comparison of different treatments regarding biological effectiveness. This is not possible by a single temperature figure; instead, temporal changes and spatial temperature inhomogeneities should be taken into account. 16 In the present prospective pilot study, we treated tumour-bearing companion animals in order to test the clinical use of a new multimodular radiofrequency (RF) applicator system and treatment planning tool for HT. By using EM, thermal and induced effect simulations, the individual placement of applicators as well as their main parameters were optimized and temperature predictions were made. During treatment, temperature probes-implanted prior to the first treatmentsupervised safe delivery, validated temperature predictions and allowed adaptation of energy delivery. For evaluating treatment intensity 2 different approaches, the cumulative equivalent minute (CEM) isodose concept and a transient thermal dose equivalent (TTDE) were used. 17 The primary goal of our study was to test the applicability of the novel HT hardware and software components in clinical tumourbearing dogs and cats, and to compare planned with actual achieved data during heating. As secondary endpoints, response to treatment was described with respect to observed toxicity and local tumour response in the treated animal patients.
| MATERIALS AND METHODS
HT treatment was performed using a novel applicator prototype (developed by the IT'IS Foundation, Zurich, Switzerland) with the possibility of grouping multiple elements to form an array with a flexible number and position of the elements, and an integrated closed-loop radiated electromagnetic field (EMF) feedback control system. Thermal delivery was prospectively planned with treatment-planning tool that was developed based on the computational life sciences platform Sim4Life
(ZMT Zurich MedTech, Zurich, Switzerland). The treatment-planning tool was empowered to segment individual animal patients with iSEG:
Medical Image Segmentation Tool Set (iSEG) (ZMT Zurich MedTech), to semi-automatically optimize the placement of the applicator system, to determine personalized steering parameters using a dedicated field optimizer, and to perform analysis and visualization functionality. For the current investigation, feline and canine tumour animal patients with various types of inoperable cancers were included. In this experimental clinical setting, we used multiple temperature probes in order to validate the predicted intra-tumoural and superficial temperatures achieved during treatment. The measurement data obtained was then used to ensure that the applied treatment corresponds the predictions made during planning and allowed real-time adjustment in order to provide effective and safe heating. 
| Animal patient criteria

| HT and RT treatment planning
A treatment planning computed tomography (CT) was acquired in an individually prepared immobilization device: animals were positioned in a vacuum cushion (BlueBag BodyFix, Elekta AB, Stockholm, Sweden) and a custom-made bite block was used, if required. 18 Immobilization also served the purpose of achieving reproducible positioning and to align planning and treatment. A non-contrast and contrastenhanced study was performed to visualize the tumour. Subsequently, temperature transponder seeds (IPTT-300, Bio Medic Data Systems, Inc., Seaford, Delaware) were implanted in a minimally invasive manner in viable tumour areas, avoiding cystic or necrotic regions, which are likely to result in sensor migration. After implantation, an additional CT study was performed to confirm the transponder location. Both, the initial CT (without transponders) and the postinjection CT (with transponders) were later used for segmentation.
RT treatment planning was performed in all cases by a boardcertified radiation oncologist (C.R.B.) on the basis of 3D CT data using the Eclipse External Beam Planning system version 10.0 (Varian Oncology Systems, Palo Alto, California). Tumour related volumes were contoured as follows: the gross tumour volume (GTV) was delineated using co-registered contrast-enhanced CT sequences; the clinical target volume (CTV), accounting for subclinical microscopic disease extension, was defined according to the radiation oncologist's choice for the respective disease; and, based on tumour location, the CTV-planning target volume (PTV) margin extension was a 3-D extension by 2 to 5 mm to define the PTV, accounting for systematic and random uncertainties. Organs at risk were specified as required.
For HT treatment planning, the CT images and the previously defined tumour (GTV) and organs at risk related volumes from the RT treatment planning (RTstruct DICOM images) were imported into iSEG. This segmentation toolbox features a set of flexible (semi-) 
| Applicator
The newly designed applicator prototype ( Figure 1 ) consists of different elements, including a cavity-backed slot antenna, 24 . In this case, the vaccine-associated sarcoma is located on the right caudodorsal abdominal wall (only the caudal abdomen and pelvic region relevant for reliable modelling is segmented) Switzerland), which was placed between the water bolus and the skin.
To quantify the treatment intensity of applied heat, thermal dosimetry was used, meaning that the temperature as function of time was translated into a biological effect. It is important to note that thermometry alone is not sufficient to achieve this; the temperatures acquired with thermometry need to be transformed into thermal doses. Thermal dose was calculated for each temperature sensor and was converted to an equivalent exposure time in minutes at a reference temperature of 43 C, using the following formula from 
First order kinetics are assumed; the coefficient k 1 is given by the
Þ , where
, T is the temperature in (K) and t is the time. At time of progression, animal patients were allowed to receive additional treatment (eg, metronomic chemotherapy or surgical debulking). Radiation-induced toxicity was scored using the Veterinary Radiation Therapy Oncology Group (VRTOG) scheme each time RT was applied, and at regular rechecks. 34 HT-specific side effects were graded according to the Common Toxicity Criteria Adverse Events (CTCAE) v4.03 35 and Quality Management in Hyperthermia (QMHT) 35 on each treatment day and on all follow-up examinations.
| Statistical analysis
Data was compiled in Excel (Microsoft, Redmond, Washington).
Descriptive statistics are reported on the following variables:
(1) pre-treatment longest tumour diameter, (2) maximum reduction of the longest diameter after treatment, (3) reduction in tumour volume, (4) time to greatest response and (5) median skin temperature during FIGURE 2 Graphical illustration of a 5 × 6 Gy radiation therapy protocol in combination with hyperthermia used for the treatment of soft tissue sarcoma treatment, as well as on the 3 thermal dose candidates (6) CEM43, 3 | RESULTS
| Animal patient and tumour characteristics
Eight client-owned companion animals were included into a combined thermoradiotherapy protocol receiving in total 3 sessions of HT as an additive to hypofractionated RT.
Animal and tumour characteristics are summarized in Table 1 .
Two animals were treated with a deviating RT protocol: in 1 dog (ani- once daily) and a non-steroidal anti-inflammatory drug (piroxicam or firocoxib using the recommended standard dose) 29 was initiated. In animal 5 metronomic chemotherapy was discontinued after 151 days due to massive disease progression and oral Temozolomide was administered once daily for 5 consecutive days at a dosage of 60 mg m −2 every 28 days. 30 The dog received 2 such cycles until treatment was discontinued and the dog euthanized due to disease progression.
( Table 1) 3.4 | Side effects (toxicity)
Acute thermal side effects were seen in 1 animal (animal 1). The dog was in slight pain (increase in heart and respiratory rate during (1) the original optimized treatment plan using a constant power strength, (2) the actual temperatures obtained from the transponders every 5 minutes, including the temperature drop at the end of the therapy for 1 of the transponders, and (3) simulation after therapy application, considering the variation of applied power during the therapy and the exact time slots when the power was turned off and the water bolus was removed (ie, the periods in which the temperature from the sensors was acquired). B, Power applied to the applicator as a function of time according to the original treatment plan and the actually applied, dynamically adjusted (based on temperature sensors) power during the session anaesthesia, degree I) and developed a mild erythema in the area of the treated skin (degree II). The treatment was continued with a power reduction and symptoms resolved spontaneously after the treatment (Table 1) . No subacute or late thermal side effects were observed in any of the animals. Radiation toxicity was mild and not more severe than previously described for the same radiation protocol: 29 grade 1 acute toxicity of the skin was seen in 7 animals (alopecia/epilation, erythema or dry desquamation) and/or in the mucous membranes (injection of the mucous membranes without mucositis) and grade 2 acute toxicity was present in the skin of 1 animal (patchy moist desquamation, without edema). Mild late side effects were seen in 5 animals with grade 1 toxicity including alopecia or leukotrichia. Transponder-related side effects were seen in 2 cases. In 1 case This included a debridement in the first case and a debulking of the tumour in the second case.
| Thermal dose calculations
Of the 24 performed HT sessions, transponder readings from different locations could be evaluated during each treatment: temperature data was available (1) In particular, large, bulky tumours have shown to challenge treatment planning in terms of achieving a homogenous temperature difficult, but gives an indication of the wide applicability of the treatment modality and system. Moreover, it should be noted that all presented animals and tumours were treated, without treatment planning-based pre-selection, reflecting expected heatability.
| CONCLUSION
In conclusion, our study shows that the novel HT system provides individually adaptive, flexible and safe HT treatments using a patientspecific treatment-planning tool and a closed-loop feedback control system to ensure that the applied treatment corresponds to predictions. All but 1 animal experienced improved quality of life in a palliative-intent treatment setting. Response cannot be an endpoint due to the limited number of heterogeneous cases, however, the study provides a proof of principle that effective, homogenous heating can be planned and verified.
Future work should focus on image-based systems enabling replanning and adaption of the treatment plans shortly before each session based on the current anatomical and physiological conditions to consider anatomical changes during therapy. In the future, and considering the lessons learned in the treatment of these first animals, computational planning should also be used to select patients and decide on the suitability of providing HT treatment.
